Zynex - Double Shot of Good News

Zynex - Double Shot of Good News

Brian Marckx, CFA

Zynex Inc. (ZYXI - Analyst Report) announced more positive news over the last few days.  In a September 23, 2011 8-K filing Zynex reported that they came to terms with Anthem Blue Cross Blue Shield relative to a dispute between the two companies over refund requests.  As a reminder, in April 2010 Zynex received a refund request from Anthem in the amount of $1.3 million.  Zynex estimated at the time that they had about $1.5 million worth of rebillings that were not properly reimbursed by Anthem  - which would more than offset Anthem's claim.

The 8-K notes that, per a settlement agreement, Zynex will pay Anthem $226k and all claims will be resolved.  Zynex will make an initial $60k payment and will pay the balance over the next 12 months.  We view this settlement as good news for Zynex and removes an issue that had been hanging over the company since the initial claim was filed by Anthem.  

Zynex came out with more encouraging news this morning with the announcement that NexWave, Zynex's next generation electrotherapy device, received FDA 510(k) clearance.  While approval comes somewhat later than we had initially anticipated, we expect NexWave to be a solid complement to Zynex's current line-up of electrotherapy products and contribute to overall sales growth.             

We cover Zynex with an Outperform rating.  

To view our most recent research reports and subscribe to our daily morning email alert, visit http://scr.zacks.com/. Please email scr@zacks.com with ZYXI as the subject to request a copy of the full research report.

Follow Zacks Small Cap Research on Twitter at Twitter.com/ZacksSmallCap

Read the full analyst report on ZYXI